Private company

Prometheus Biosciences, Inc.

American pharmaceutical preparations company, incorporated in Delaware.

Last updated Oct 18, 2026.

Overview

IndustryPharmaceutical Preparations
HeadquartersDE
Incorporated inDE²
Business address3050 Science Park Road, San Diego, Ca 92121²
Filer categoryLarge accelerated filer²

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-2141.0%Operating margin³

-2081.8%Net margin³

117.6%Revenue growth, 2022³

-21.0%Return on equity³

-$126.0MFree cash flow³

Where the money goes

Where each dollar of revenue went, fiscal 2022

Research and development

Research and development100¢$112.8M

Out of $6.8M in revenue.³ The company lost money this year.

Financial statements

Revenue³$6.8M in 2022+454% since 2020

Operating income³-$145.8M in 2022+403% since 2020

Net income³-$141.8M in 2022+282% since 2020

Fiscal year	2020	2021	2022
Revenue	$1.2M³	$3.1M³	$6.8M³
Research and development	$19.1M³	$62.4M³	$112.8M³
Operating income	-$29.0M³	-$87.8M³	-$145.8M³
Interest	$2.1M³	$861.0K³
Income tax		$0³	$0³
Net income	-$37.1M³	-$90.2M³	-$141.8M³
Earnings per share	-$24.78³	-$2.88³	-$3.49³
Earnings per share (diluted)	-$24.78³	-$2.88³	-$3.49³

Total assets⁷³$740.8M in 2022+1142% since 2020

Total liabilities⁷³$64.8M in 2022+108% since 2020

Shareholders’ equity³$676.0M in 2022

Cash³⁷$292.4M in 2022+6471% since 2019

Fiscal year	2019	2020	2021	2022
Cash	$4.5M³	$54.2M⁷	$257.3M³	$292.4M³
Current assets		$57.5M⁷	$265.4M³	$708.2M³
Total assets		$59.6M⁷	$267.8M³	$740.8M³
Current liabilities		$15.3M⁷	$16.4M³	$22.8M³
Long-term debt		$7.4M⁷
Total liabilities		$31.2M⁷	$32.6M³	$64.8M³
Shareholders’ equity	-$37.0M³	-$97.5M³	$235.2M³	$676.0M³
Shares outstanding		1.7M shares⁷	38.9M shares³	46.8M shares³

Cash from operations³-$123.3M in 2022+340% since 2020

Capital spending³$2.7M in 2022+1225% since 2020

Free cash flow³-$126.0M in 2022+346% since 2020

Fiscal year	2020	2021	2022
Cash from operations	-$28.0M³	-$63.5M³	-$123.3M³
Capital spending	$204.0K³	$1.1M³	$2.7M³
Free cash flow	-$28.2M	-$64.6M	-$126.0M

Compare Prometheus Biosciences, Inc. with another company

Leadership

Who has led Prometheus Biosciences, Inc., and when. Pick a name to see everywhere that person has worked.

2025

Chief executive officerMark C. McKenna Mar 11, 2021 to Jun 16, 2023⁸
ChairMark C. McKenna Nov 16, 2021 to Jun 16, 2023⁹
PresidentMark C. McKenna Mar 11, 2021 to Jun 16, 2023⁸
Chief financial officerKeith W. Marshall Mar 11, 2021 to Jun 16, 2023¹⁰
Chief operating officerMark Stenhouse Mar 11, 2021 to Jun 16, 2023¹¹

Board members and other officers (11)

Chief Medical OfficerAllison Luo Mar 11, 2021 to Nov 16, 2021¹²
Board memberBihua Chen Mar 11, 2021 to Mar 18, 2021¹³
Board memberHelen C. Adams Mar 11, 2021 to Jun 16, 2023¹⁴
Board memberJames Laur Mar 11, 2021 to Jun 16, 2023¹⁵
Board memberJoseph C. Papa Mar 11, 2021 to Jun 16, 2023¹⁶
Board memberJudith L. Swain Mar 11, 2021 to Jun 16, 2023¹⁷
Board memberMark C. McKenna Mar 11, 2021 to Mar 11, 2021⁸
Board memberMartin Hendrix Mar 11, 2021 to Jun 16, 2023¹⁸
Board memberMary T. Szela Mar 11, 2021 to Jun 16, 2023¹⁹
Board memberFred Hassan May 17, 2021 to Jun 16, 2023²⁰
General counselTimothy K. Andrews Mar 11, 2021 to Nov 16, 2021²¹

Former names

Precision IBD, Inc.Oct 10, 2017 to Jul 15, 2019²

Timeline

Mar 11, 2021New chief executive Mark C. McKenna becomes CEO⁸

Filings

112 filings to the SEC since October 2021: 3 annual reports, 5 quarterly reports, 20 major events, 54 insider forms, 14 large holders, 16 other. The latest 20:

The 112 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last three years, summarized. The full record is on SEC EDGAR.

Insider trades and holders

Large holders

Investors who own more than 5% must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively. 14 such filings since October 2021, the latest 10:

Mar 8, 2023SC 13G/A
Feb 17, 2023SC 13G/A
Feb 14, 2023SC 13G/A
Feb 14, 2023SC 13G/A
Feb 14, 2023SC 13G/A
Feb 14, 2023SC 13G/A
Feb 14, 2023SC 13G/A
Jun 7, 2022SC 13G
Feb 14, 2022SC 13G
Feb 14, 2022SC 13G/A

From Forms 4 and Schedules 13D and 13G filed with the SEC.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARPrometheus Biosciences, Inc. filings on SEC EDGAR
2
SEC EDGARPrometheus Biosciences, Inc. filings on SEC EDGAR
3
SEC EDGARPrometheus Biosciences, Inc. 10-K for fiscal 2022
4
SEC EDGARPrometheus Biosciences, Inc. 10-Q for fiscal 2022
5
SEC EDGARPrometheus Biosciences, Inc. 10-Q for fiscal 2022
6
SEC EDGARPrometheus Biosciences, Inc. 10-Q for fiscal 2023
7
SEC EDGARPrometheus Biosciences, Inc. 10-K for fiscal 2020
8
SEC EDGARMark C. McKenna, Chief executive officer
9
SEC EDGARMark C. McKenna, Chair
10
SEC EDGARKeith W. Marshall, Chief financial officer
11
SEC EDGARMark Stenhouse, Chief operating officer
12
SEC EDGARAllison Luo, Chief Medical Officer
13
SEC EDGARBihua Chen, Board member
14
SEC EDGARHelen C. Adams, Board member
15
SEC EDGARJames Laur, Board member
16
SEC EDGARJoseph C. Papa, Board member
17
SEC EDGARJudith L. Swain, Board member
18
SEC EDGARMartin Hendrix, Board member
19
SEC EDGARMary T. Szela, Board member
20
SEC EDGARFred Hassan, Board member
21
SEC EDGARTimothy K. Andrews, General counsel